CCL3L1 Copy Number is a Strong Genetic Determinant of HIV Seropositivity in Caucasian Intravenous Drug Users

Overview

Journal J Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2010 Jan 26

PMID 20095832

Citations 20

Authors

Kristi Huik

Maarja Sadam

Tonis Karki

Radko Avi

Tonu Krispin

Piret Paap

Kristi Ruutel

Anneli Uuskula

Ave Talu

Katri Abel-Ollo

Irja Lutsar

Affiliations

Soon will be listed here.

Abstract

Background: A high copy number of CCL3L1, the most potent human immunodeficiency virus (HIV)-suppressive chemokine, associates with reduced HIV susceptibility. Whether CCL3L1 influences acquisition of multiple blood-borne infections (eg, hepatitis C virus [HCV], HIV, and hepatitis B virus [HBV] infections), which occur commonly among injection drug users (IDUs), is unknown.

Methods: We determined CCL3L1 copy number by real-time polymerase chain reaction among 374 Caucasian IDUs from Estonia; 285 were HCV positive, 208 were HIV positive, 177 were HCV and HIV positive, and 57 were HCV and HIV negative.

Results: In univariate and multivariate analyses, HCV and HBV seropositivity and duration of IDU each strongly predicted HIV seropositivity. A high CCL3L1 copy number (>2) was associated with an 80% reduced risk of acquiring HIV infection after adjusting for age, sex, HCV and HBV status, CCR5-Delta32 polymorphism, and IDU duration (odds ratio, 0.20; 95% confidence interval, 0.09-0.45). By contrast, CCL3L1 gene dose did not influence HCV seropositivity. Among HCV-positive IDUs, there was a 3.5-fold overrepresentation and 65% underrepresentation of a high CCL3L1 copy number among HCV-positive, HIV-negative subjects and HCV-positive, HIV-positive subjects, respectively.

Conclusion: Among IDUs with extensive exposure to HCV and HIV, CCL3L1 copy number is a major determinant of HIV seropositivity but not of HCV seropositivity. The contrasting distribution of a protective high CCL3L1 copy number among HCV-positive, HIV-negative IDUs versus HCV-positive, HIV-positive IDUs may reflect that HIV preferentially selects for subjects with a low CCL3L1 gene dose.

Citing Articles

An atlas of immune cell transcriptomes in human immunodeficiency virus-infected immunological non-responders identified marker genes that control viral replication.

Chen Y, Li X, Liu S, Ao W, Lin J, Li Z Chin Med J (Engl). 2023; 136(22):2694-2705.

PMID: 37914674 PMC: 10684209. DOI: 10.1097/CM9.0000000000002918.

Comparative physiological anthropogeny: exploring molecular underpinnings of distinctly human phenotypes.

Vaill M, Kawanishi K, Varki N, Gagneux P, Varki A Physiol Rev. 2023; 103(3):2171-2229.

PMID: 36603157 PMC: 10151058. DOI: 10.1152/physrev.00040.2021.

Deletions in Genes Participating in Innate Immune Response Modify the Clinical Course of Andes Orthohantavirus Infection.

Ribeiro G, Leon L, Perez R, Cuiza A, Vial P, Ferres M Viruses. 2019; 11(8).

PMID: 31349540 PMC: 6723883. DOI: 10.3390/v11080680.

A CCL5 Haplotype Is Associated with Low Seropositivity Rate of HCV Infection in People Who Inject Drugs.

Huik K, Avi R, Pauskar M, Kallas E, Jogeda E, Karki T PLoS One. 2016; 11(6):e0156850.

PMID: 27304910 PMC: 4909289. DOI: 10.1371/journal.pone.0156850.

Human T-lymphotropic virus types 1 and 2 are rare among intravenous drug users in Eastern Europe.

Jogeda E, Avi R, Pauskar M, Kallas E, Karki T, Des Jarlais D Infect Genet Evol. 2016; 43:83-5.

PMID: 27223634 PMC: 4949113. DOI: 10.1016/j.meegid.2016.05.022.

References

Modi W . CCL3L1 and CCL4L1 chemokine genes are located in a segmental duplication at chromosome 17q12. Genomics. 2004; 83(4):735-8. DOI: 10.1016/j.ygeno.2003.09.019. View

Shankar E, Solomon S, Vignesh R, Murugavel K, Sundaram M, Solomon S . GB virus infection: a silent anti-HIV panacea within?. Trans R Soc Trop Med Hyg. 2008; 102(12):1176-80. DOI: 10.1016/j.trstmh.2008.04.034. View

Lillard Jr J, Singh U, Boyaka P, Singh S, Taub D, McGhee J . MIP-1alpha and MIP-1beta differentially mediate mucosal and systemic adaptive immunity. Blood. 2002; 101(3):807-14. DOI: 10.1182/blood-2002-07-2305. View

Nakajima T, Ohtani H, Naruse T, Shibata H, Mimaya J, Terunuma H . Copy number variations of CCL3L1 and long-term prognosis of HIV-1 infection in asymptomatic HIV-infected Japanese with hemophilia. Immunogenetics. 2007; 59(10):793-8. DOI: 10.1007/s00251-007-0252-4. View

Shostakovich-Koretskaya L, Catano G, Chykarenko Z, He W, Gornalusse G, Mummidi S . Combinatorial content of CCL3L and CCL4L gene copy numbers influence HIV-AIDS susceptibility in Ukrainian children. AIDS. 2009; 23(6):679-88. PMC: 2929972. DOI: 10.1097/QAD.0b013e3283270b3f. View

Grivel J, Ito Y, Faga G, Santoro F, Shaheen F, Malnati M . Suppression of CCR5- but not CXCR4-tropic HIV-1 in lymphoid tissue by human herpesvirus 6. Nat Med. 2001; 7(11):1232-5. DOI: 10.1038/nm1101-1232. View

Williams C, Klinzman D, Yamashita T, Xiang J, Polgreen P, Rinaldo C . Persistent GB virus C infection and survival in HIV-infected men. N Engl J Med. 2004; 350(10):981-90. DOI: 10.1056/NEJMoa030107. View

Shalekoff S, Meddows-Taylor S, Schramm D, Donninger S, Gray G, Sherman G . Host CCL3L1 gene copy number in relation to HIV-1-specific CD4+ and CD8+ T-cell responses and viral load in South African women. J Acquir Immune Defic Syndr. 2008; 48(3):245-54. PMC: 2562935. DOI: 10.1097/QAI.0b013e31816fdc77. View

Platt L, Bobrova N, Rhodes T, Uuskula A, Parry J, Ruutel K . High HIV prevalence among injecting drug users in Estonia: implications for understanding the risk environment. AIDS. 2006; 20(16):2120-3. DOI: 10.1097/01.aids.0000247586.23696.20. View

10.

Lederman M, Sieg S . CCR5 and its ligands: a new axis of evil?. Nat Immunol. 2007; 8(12):1283-5. DOI: 10.1038/ni1207-1283. View

11.

Dolan M, Kulkarni H, Camargo J, He W, Smith A, Anaya J . CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms. Nat Immunol. 2007; 8(12):1324-36. DOI: 10.1038/ni1521. View

12.

Berzsenyi M, Bowden D, Kelly H, Watson K, Mijch A, Hammond R . Reduction in hepatitis C-related liver disease associated with GB virus C in human immunodeficiency virus coinfection. Gastroenterology. 2007; 133(6):1821-30. DOI: 10.1053/j.gastro.2007.08.076. View

13.

Pilotti E, Elviri L, Vicenzi E, Bertazzoni U, Re M, Allibardi S . Postgenomic up-regulation of CCL3L1 expression in HTLV-2-infected persons curtails HIV-1 replication. Blood. 2006; 109(5):1850-6. DOI: 10.1182/blood-2006-07-036046. View

14.

Townson J, Barcellos L, Nibbs R . Gene copy number regulates the production of the human chemokine CCL3-L1. Eur J Immunol. 2002; 32(10):3016-26. DOI: 10.1002/1521-4141(2002010)32:10<3016::AID-IMMU3016>3.0.CO;2-D. View

15.

Adojaan M, Kivisild T, Mannik A, Krispin T, Ustina V, Zilmer K . Predominance of a rare type of HIV-1 in Estonia. J Acquir Immune Defic Syndr. 2005; 39(5):598-605. View

16.

Alter M . Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 2005; 44(1 Suppl):S6-9. DOI: 10.1016/j.jhep.2005.11.004. View

17.

Cocchi F, Devico A, Garzino-Demo A, Arya S, Gallo R, Lusso P . Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science. 1995; 270(5243):1811-5. DOI: 10.1126/science.270.5243.1811. View

18.

Karpus W, Lukacs N, Kennedy K, Smith W, Hurst S, Barrett T . Differential CC chemokine-induced enhancement of T helper cell cytokine production. J Immunol. 1997; 158(9):4129-36. View

19.

Martin M, Lederman M, Hutcheson H, Goedert J, Nelson G, van Kooyk Y . Association of DC-SIGN promoter polymorphism with increased risk for parenteral, but not mucosal, acquisition of human immunodeficiency virus type 1 infection. J Virol. 2004; 78(24):14053-6. PMC: 533922. DOI: 10.1128/JVI.78.24.14053-14056.2004. View

20.

Uuskula A, McNutt L, DeHovitz J, Fischer K, Heimer R . High prevalence of blood-borne virus infections and high-risk behaviour among injecting drug users in Tallinn, Estonia. Int J STD AIDS. 2007; 18(1):41-6. PMC: 2925660. DOI: 10.1258/095646207779949907. View